News Sumitomo Pharma Co., Ltd.

Equities

4506

JP3495000006

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-05-21 am EDT			5-day change	1st Jan Change
309 ^JPY	-8.85%		-25.18%	-33.69%

May. 09	Sumitomo Pharma Co., Ltd. agreed to acquire MELTz Business of MELTIN MMI Co., Ltd.	CI
May. 07	Profit-Taking, China Outlooks Churn Asian Stock Markets	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Sumitomo Pharma : Posted Conference on FY2023 Financial Results	May. 20	PU
Sumitomo Chemical Co., Ltd. - Announcement of Finance Income, Restructuring Costs, and Extraordinary Loss in Non-consolidated Financial Statements	May. 16	AQ
Sumitomo Pharma : May 14, 2024 Conference on FY2023 (April 1, 2023 to March 31, 2024) Financial Results	May. 14	PU
Sumitomo Pharma : Appoints Toru Kimura as President and CEO and Changes in Board of Directors Including Representative Directors, Executive Officer, and the Positions Assumed by Executive Officers	May. 14	PU
Sumitomo Pharma : Presentation Material (Conference on FY2023 Financial Results)	May. 14	PU
Sumitomo Pharma : Start of Phase 1 Clinical Study on Novel Universal Influenza Vaccine Candidate	May. 14	PU
Sumitomo Pharma : Notice of Company Split (Simplified Absorption-type Company Split) of the Frontier Business and Notice of Business Acquisition by a Wholly-Owned Subsidiary of the Company	May. 09	PU
Sumitomo Pharma Co., Ltd. agreed to acquire MELTz Business of MELTIN MMI Co., Ltd.	May. 08	CI
Profit-Taking, China Outlooks Churn Asian Stock Markets	May. 07	MT
Sumitomo Pharma : Posted Conference on Financial Forecasts Revision for FY2023 and Financial Forecasts for FY2024	May. 07	PU
Sumitomo Pharma : May 01, 2024 Conference on Financial Forecasts Revision for FY2023 and Financial Forecasts for FY2024 transcript	May. 07	PU
Fed Outlook, Earnings Season Roil Asian Stock Markets	May. 02	MT
Sumitomo Pharma Sees Impairment Losses and Restructuring Expenses in Fiscal 2024	May. 02	MT
Sumitomo Pharma Expects Substantial Valuation Loss on Subsidiary Shares; Assures No Impact on Consolidated Profit	May. 02	MT
Sumitomo Pharma : May 01, 2024 Conference on Financial Forecasts Revision for FY2023 and Financial Forecasts for FY2024	May. 02	PU
Sumitomo Pharma : Presentation Material (Conference on Financial Forecasts Revision for FY2023 and Financial Forecasts for FY2024)	Apr. 29	PU
Lull in Geopolitical Tensions Lifts Asian Stock Markets	Apr. 22	MT
Jefferies Adjusts Sumitomo Pharma’s Price Target to 420 Yen From 520 Yen, Keeps at Hold	Apr. 17	MT
Roivant Sciences Says Study of Potential Uveitis Treatment Meets Endpoints; Launches Stock Repurchase; Shares Rise	Apr. 02	MT
Roivant's anti-inflammatory drug succeeds in mid-stage study	Apr. 02	RE

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Sumitomo Pharma Co., Ltd.

Equities

4506

JP3495000006

Summary

Filters